Serial analysis of serum cardiac troponin I changes and correlation with clinical findings in 46 dogs with mitral valve disease. (25th February 2014)

• Record Type: Journal Article
• Authors: Polizopoulou, Zoe S.; Koutinas, Christos K.; Dasopoulou, Anastasia; Patsikas, Michael; York, Malcolm; Roman, Ian; Gandhi, Mitul; Patel, Sonal; Koutinas, Alexander F.; O'Brien, Peter J.
• Is Part Of: Veterinary clinical pathology. Volume 43:Number 2(2014)
• Page Start: 218
• Page End: 225
• Publication Date: 2014-02-25
• Subjects: Veterinary pathology -- Periodicals; 636.089607
• DOI: 10.1111/vcp.12124
• Languages: English
• ISSNs: 0275-6382

Abstract

<abstract abstract-type="main" id="vcp12124-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="vcp12124-sec-0001" sec-type="section"> <title>Background</title> <p>Cardiac troponin I (cTnI) is a biomarker correlated with the severity of myocardial injury. It is hypothesized that serial assessment of cTnI could provide information about the disease progression in chronic heart failure.</p> </sec> <sec id="vcp12124-sec-0002" sec-type="section"> <title>Objective</title> <p>The purpose of the study was to correlate serial serum cTnI concentrations with clinical scoring and select diagnostic imaging findings in dogs managed for mitral valve degeneration (MVD) for a period of 6 months.</p> </sec> <sec id="vcp12124-sec-0003" sec-type="section"> <title>Methods</title> <p>Client‐owned dogs with MVD were prospectively recruited for the study. The dogs were allocated into 3 groups (I, II, III) according to the severity of their clinical signs based on the classification suggested by the International Small Animal Cardiac Health Council. During the 6‐month study period, serum specimens for biochemical testing were obtained biweekly, clinical progression and response to treatment were also evaluated biweekly, and radiographic reevaluation was performed every 2 months.</p> </sec> <sec id="vcp12124-sec-0004" sec-type="section"> <title>Results</title> <p>A total of 46 dogs were evaluated. There was a marked decrease in cTnI values during the first 2 weeks after initial diagnosis, more pronounced in group III, and corresponding to the initiation of therapy and clinical stabilization of animals. Serum cTnI was significantly different (<italic>P </italic><<italic> </italic>.05) among the 3 dog groups throughout the study period. The interaction between Group and Period was significant in group III, indicating an upward cTnI trend evident in severely affected animals. A positive correlation was demonstrated in all groups between serum cTnI and clinical scoring.</p> </sec> <sec id="vcp12124-sec-0005" sec-type="section"> <title>Conclusion</title> <p>Long‐term management of MVD in dogs could benefit from the serial measurement of cTnI.</p> </sec> </abstract>